Last March, a guy named Kevin in Phoenix emailed his compounding pharmacy at 11 p.m. in a low-grade panic. He'd just reconstituted what he thought was a 2 mg vial of CJC-1295 with DAC, drawn up 100 mcg into an insulin syringe, and injected it before bed. "My buddy told me to do 100 mcg at night, same as his protocol," he wrote. The problem: Kevin had the DAC version. His buddy was on Modified GRF 1-29 (no-DAC). A 100 mcg dose of the DAC version, taken once at bedtime with no plan to dose again for a week, isn't dangerous. But it's roughly a tenth of a useful weekly dose. Kevin had just wasted his vial on mouse-sized portions because nobody told him these are two fundamentally different drugs that happen to share a name.
This confusion is the single biggest dosing error in the peptide space, and it's entirely avoidable once you understand what you're actually holding.
CJC-1295 is not FDA-approved. It is a compounded research peptide dispensed by licensed pharmacies for individual patients under a valid prescription. Individual results vary.
The Only Thing That Matters: Which Version Are You Using?
CJC-1295 dosage depends entirely on which version you have. Full stop.
CJC-1295 with DAC (Drug Affinity Complex) has a half-life of roughly 6 to 8 days. Standard dosing: 1 to 2 mg total per week, split into one or two injections.
CJC-1295 without DAC (Modified GRF 1-29) has a half-life of roughly 30 minutes. Standard dosing: 100 to 300 mcg per injection, 1 to 3 times daily.
Read those numbers again. One is measured in milligrams per week. The other in micrograms per day. Confusing them will give you either nothing or way too much.
Quick-Reference Table
With DAC:
- Per injection: 0.5 to 1 mg (500 to 1,000 mcg)
- Weekly total: 1 to 2 mg
- Frequency: 1 to 2 times per week
- Half-life: 6 to 8 days
- GH pattern: sustained baseline elevation
No-DAC (Mod GRF 1-29):
- Per injection: 100 to 300 mcg
- Daily total: 100 to 900 mcg
- Frequency: 1 to 3 times daily
- Half-life: ~30 minutes
- GH pattern: pulsatile release
How We Ended Up With Two Peptides Sharing One Name
The original CJC-1295 was developed by ConjuChem and characterized in published research (Teichman SL et al., 2006, Journal of Clinical Endocrinology & Metabolism). The clever part was the DAC component, a maleimidopropionic acid attachment that binds the peptide to albumin in the bloodstream. That albumin binding is what stretches the half-life from minutes to days. Think of it like a time-release capsule versus a fast-dissolving tablet, except the mechanism is the peptide literally hitching a ride on a protein already circulating in your blood.
Modified GRF 1-29 is the same 29-amino acid sequence without the albumin-binding attachment. Its half-life drops back to around 30 minutes, which actually mirrors the way your hypothalamus naturally releases GHRH in short bursts.
The practical result:
- The DAC version keeps GHRH receptors stimulated for days at a time.
- The no-DAC version fires a quick pulse and clears. More natural. More injections.
Who Picks Which (and Why)
Here's the thing: neither version is categorically better. The choice is about what you're willing to trade.
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →DAC tends to suit people who want one or two injections per week and don't mind sustained GH elevation. It's popular among patients who stack it with daily ipamorelin, using DAC for the baseline and ipamorelin for the pulse. Convenience is the main selling point.
No-DAC tends to suit people who want their GH release to look more like what a healthy 25-year-old pituitary produces: sharp spikes followed by clearance. Some longevity-focused clinicians prefer it because sustained IGF-1 elevation (the kind DAC can produce) raises theoretical concerns they'd rather avoid. The tradeoff is daily injections, sometimes multiple.
My honest take: if you're not willing to inject daily, don't pick no-DAC and then skip doses. A sloppy no-DAC protocol probably underperforms a consistent DAC protocol. Consistency matters more than theoretical superiority.
DAC Protocol: The Nuts and Bolts
A standard DAC protocol:
- Reconstitute a 2 mg vial with 2 mL bacteriostatic water (gives you 1 mg/mL, or 1,000 mcg/mL)
- Inject 0.5 to 1 mg subcutaneously
- Frequency: once or twice weekly. Monday only works fine. Monday and Thursday is common for the 2 mg/week range.
- If stacking ipamorelin: 200 to 300 mcg ipamorelin daily, on its own schedule, separate injection
- Cycle length: 8 to 12 weeks on, 4 weeks off
Titration for DAC:
- Week 1: 0.5 mg, once
- Week 2 onward: 1 mg once weekly (or split into two 0.5 mg doses)
Because the half-life is 6 to 8 days, timing within the week barely matters. Most people pick a day and stick with it for simplicity.
No-DAC Protocol: More Injections, More Precision
A standard no-DAC protocol:
- Reconstitute a 5 mg vial with 2 mL bacteriostatic water (2.5 mg/mL, or 2,500 mcg/mL)
- 0.1 mL on an insulin syringe = 250 mcg
- 0.04 mL (4 units) = 100 mcg
- 0.12 mL (12 units) = 300 mcg
- Inject 100 to 300 mcg subcutaneously, 1 to 3 times daily
- Often combined in the same syringe with ipamorelin (100 to 200 mcg CJC no-DAC + 200 to 300 mcg ipamorelin)
- Cycle: 8 to 12 weeks on, 4 weeks off
Titration for no-DAC:
- Week 1: 100 mcg once daily, pre-bed
- Week 2: 200 mcg once daily, pre-bed
- Week 3 onward: 200 to 300 mcg, 2 to 3 times daily
When to Inject (No-DAC)
Pre-bed is the priority dose. It aligns with the body's natural overnight GH surge during slow-wave sleep. If you're only doing one injection a day, this is the one.
Post-workout (within 30 minutes of finishing) extends the natural exercise-induced GH pulse. Good second dose.
Fasted morning adds a third pulse. No food for two hours prior. Carbohydrates blunt the GH response, so don't eat a bagel and then inject.
Injection Sites and Storage
Both versions go subcutaneous. Rotate between:
- Abdomen (two inches away from the navel)
- Outer thigh
- Love handle area
- Upper outer hip
Rotation reduces the (small) risk of localized irritation or lipodystrophy.
Storage:
- Unreconstituted vials: refrigerate at 2 to 8°C
- Reconstituted vials: refrigerate, use within 30 days
- Never freeze a reconstituted vial
- Swirl gently during reconstitution. Do not shake it like a cocktail.
The Mistakes That Actually Happen
I keep a running list of the dosing errors that come up in clinical consultations and online forums. These are the repeat offenders:
DAC-specific:
- Using DAC dosing on a no-DAC product (massive underdose, basically nothing happens)
- Splitting DAC into daily injections (pointless with a week-long half-life)
- Going above 2 mg weekly without clinical guidance
No-DAC-specific:
- Using no-DAC at DAC-style doses, like 1 mg once a week (wildly wrong, either a waste or an overdose depending on how you look at it)
- Once-weekly no-DAC dosing (the peptide clears in 30 minutes, so weekly dosing means you get one brief pulse per week)
- Injecting right after a meal
Both versions:
- Confusing which product you actually have (the Kevin problem)
- Running continuously for months without an off-period
- Stacking with sermorelin, which is also a GHRH analog. That's redundant, like taking two different brands of ibuprofen at the same time.
Cycling: Don't Skip the Off-Period
Standard approach: 8 to 12 weeks on, 4 weeks off. Some patients alternate 12 on / 4 off across multiple years, with annual bloodwork to check IGF-1, fasting glucose, and other relevant markers. The off-period isn't arbitrary. Receptor desensitization is real, and periodic breaks help maintain responsiveness.
FAQ
How do I know which version I have?
Check the pharmacy label. CJC-1295 with DAC will be specified as "with DAC" or "with Drug Affinity Complex." Modified GRF 1-29 or "no-DAC" is the short half-life version. If your label is ambiguous, call the pharmacy before injecting. The dosing patterns are different enough that mixing them up will produce either no meaningful effect or supraphysiologic exposure.
Can I switch between DAC and no-DAC mid-cycle?
Not recommended. Each protocol is built around its respective half-life. Switching mid-cycle effectively starts a new protocol from scratch, and you'll have an awkward overlap period if DAC is still clearing your system.
Is DAC always better for convenience?
Yes, purely in terms of injection frequency. But convenience is one factor among several. Pulsatile physiology, longevity considerations, stacking compatibility with ipamorelin (same-syringe vs. separate), and your tolerance for daily injections all play into the decision.
What if I miss a no-DAC dose?
Resume at the next scheduled dose. Don't double up. An occasional missed dose won't invalidate a cycle. If you're missing doses regularly, that's a sign the protocol doesn't fit your life and you might be better served by DAC.
What if I miss a DAC dose?
If you're within 24 to 48 hours of when you should have taken it, go ahead and take it. If it's been longer than that, skip to the next scheduled dose. The 6 to 8 day half-life gives you a real buffer here.
Can I combine CJC-1295 and ipamorelin in the same syringe?
With the no-DAC version, yes. This is common practice. With the DAC version, they're typically injected separately because their schedules don't align (DAC weekly, ipamorelin daily).
How long before I notice anything?
Most patients report changes in sleep quality within the first two weeks. Body composition shifts (if they occur) typically take 6 to 8 weeks to become noticeable. Bloodwork changes in IGF-1 can show up sooner.
Related Reading
---
Disclaimer: CJC-1295 is not FDA-approved. It is a compounded research peptide dispensed by licensed pharmacies for individual patients under a valid prescription. This article is for educational purposes and does not constitute medical advice. Individual results vary. Always consult a licensed prescribing clinician before starting any compounded peptide protocol.
Citation: Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.